Cognition: Zervimesine AD Treatment Program FDA Alignment Means "Strong Buy" Rating (NASDAQ:CGTX)

I rate Cognition Therapeutics a Strong Buy due to FDA alignment on two pivotal phase 3 trials zervimesine in mild-to-moderate Alzheimer's patients with low...